USFDA approves Pfizer’s encorafenib+binimetinib for BRAF V600E-mutant metastatic non-small cell lung cancer (NSCLC)

The US FDA’s approval is based on data from the ongoing Phase 2 PHAROS clinical trial (NCT03915951), an open-label, multicenter, single-arm study examining BRAFTOVI+MEKTOVI combination therapy in both treatment-naïve and previously treated patients with BRAF V600E-mutant metastatic NSCLC.